Basilicata

Abstract

In Basilicata region 57,5% of women (aged 25-64) are screened regularly, meaning every 3 years. Considering regional tariffs and vaccine acquisition cost, the vaccination of 12-year-old girls with a 90% coverage could prevent 14 cases of cervicocarcinoma and 6 related deaths and thus results to be cost-effective (20.169 €/QALY). When the vaccination programme is extended to 16-year-old girls a further 15 cancer cases and 6 deaths could be prevented, with a very similar cost-effectiveness ratio. In Basilicata region, the net cost for woman vaccinated is 185 € for the single cohort and 189 € for the multiple cohort.

Keywords

• basilicata
• hpv vaccination
• economic & clinical impact